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Abstract 
 
Background: The development of spontaneous kidney transplant tolerance has been associated 
with numerous B cell-related immune alterations. We have previously shown that tolerant 
recipients exhibit reduced B cell receptor (BCR) signalling and higher IL-10 production than 
healthy volunteers. However, it is unclear whether CD4
+
T cells from tolerant recipients also 
display an antiinflammatory profile that could contribute to graft maintenance. Methods: CD4
+
T 
cells were isolated from kidney transplant recipients who were identified as being tolerant 
recipients, patients with chronic-rejection or healthy volunteers. CD4
+
T cells from the 3 groups 
were compared in terms of their gene expression profile, phenotype and functionally upon 
activation. Results: Gene expression analysis of transcription factors and signalling proteins, in 
addition to surface proteins expression and cytokine production, revealed that tolerant recipients 
possessed fewer Th17 cells and exhibited reduced Th17 responses, relative to patients with 
chronic rejection or healthy volunteers. Furthermore, impaired TCR signalling and altered 
cytokine cooperation by monocytes contributed to the development of Th17 cells in tolerant 
recipients. Conclusions: These data suggest that defective proinflammatory Th17 responses may 
contribute to the prolonged graft survival and stable graft function, which is observed in tolerant 
recipients in the absence of immunosuppressive agents.    
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Introduction 
Kidney transplantation is the gold-standard therapeutic option for treating end-stage renal 
diseases but the benefits of this approach are limited by graft rejection. The ideal scenario 
following transplantation is the development of clinical “operational tolerance”, whereby the 
allograft is stably maintained and functions normally in the absence of immunosuppression
1-3
. 
However, this is a rare event, which seldom occurs in kidney transplant recipients.  
 
The development of operational tolerance has been associated with the maintenance of B 
cell numbers and an increased expression of B cell-related genes
4-7
. However, the role of other 
lymphocyte subsets in the development of operational tolerance remains unclear. In 2006, Louis 
et al, compared the phenotype of peripheral blood mononuclear cells (PBMC) between i) tolerant 
renal transplant recipients; ii) recipients with chronic-rejection or stable graft function under 
immunosuppression; and iii) healthy individuals
8
. No significant difference in terms of 
percentages of T cells, proliferation or cytokine production between groups was observed
8
. The 
authors demonstrated that recipients with chronic-rejection possessed significantly fewer 
peripheral CD25
hi
CD4
+
T cells than tolerant recipients and healthy individuals, suggesting that 
patients with chronic-rejection had a deficit in regulatory T cells, as tolerant recipients displayed 
a similar profile to healthy individuals. Conversely, no significant differences were observed in 
the relative ratios of T cell subsets, proliferation or cytokine production between the groups 
analysed
8
. In 2007, Brouard et al, proceeded to identify peripheral biomarkers for operational 
tolerance
9
. By comparing the gene expression profiles of 75 renal-transplant patients, it was 
demonstrated that genes characterizing proinflammatory Th1/Th2 responses such as TNF-α, IL-4 
and IL-10 were consistently reduced in tolerant recipients, compared to patients with chronic-
AC
CE
PT
ED
8 
rejection
9
. Furthermore, 90% of known proinflammatory cytokines were also reduced, whereas 
FOXP3 expression was increased in tolerant patients, compared to patients with chronic-
rejection
9
. The authors highlighted that their tolerant patients did not display clinical evidence of 
immune-incompetency, corroborating a previous study in which patients were evaluated for IFN-
γ responses in vitro after influenza vaccination10. However, in the latter study, a trend was 
observed for tolerant recipients to exhibit inferior immune-responses, relative to patients under 
immunosuppression or healthy volunteers. However, this finding did not reach statistical 
significance, possibly due to the low number of tolerant patients analysed (n=4)
10
.  
 
We reported that CD4
+
T cells from tolerant recipients exhibited hyporesponsiveness to 
donor antigens and a higher ratio of FoxP3/α-1,2-mannosidase gene expression compared to 
patients with chronic-rejection
4
. In addition, we recently demonstrated that CD4
+
T cells from 
tolerant recipients were defective in their ability to produce IL-2 and IL-4 following TCR 
activation, relative to healthy volunteers
11
. Furthermore, we showed a tendency for B cells from 
tolerant recipients to be hyporesponsive, compared to cells isolated from healthy volunteers
11,12
. 
As such, we hypothesized that CD4
+
T cells from tolerant recipient would exhibit reduced 
effector responses compared to patients with chronic-rejection and healthy volunteers. T cell 
responses from a cohort of tolerant renal transplant recipients were compared with age/gender-
matched healthy volunteers and patients with chronic-rejection. The data presented demonstrate 
that tolerant patients possess fewer Th17 cells and exhibit reduced TCR signalling, compared to 
healthy controls and patients with chronic-rejection. Together, these results suggest that a 
decrease in Th17 cell frequency/response and a consequential reduction in IL-17 production in 
tolerant patients may contribute to prolonged allograft survival. 
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Materials and Methods 
Patients  
Peripheral blood samples were acquired from renal transplant recipients and healthy 
volunteers as part of the Genetic Analysis & Monitoring of Biomarker of Immunological 
Tolerance (GAMBIT) study with informed consent and ethical approval (Institute of Child 
Health/Great Ormond Street Hospital; REC: 09/H0713/12) in accordance with the principles of 
the Declarations of Helsinki. Tolerant recipients (n=17) were defined as having a functionally 
stable transplanted kidney without immunosuppression for more than 1 year. Patients with 
chronic-rejection (n=32) were defined as kidney transplant recipients with graft dysfunction, 
despite adequate immunosuppression, with a recent biopsy showing signs of immunologically 
driven chronic-rejection in accordance with the BANFF Criteria
13
. Healthy controls (n=12) were 
volunteers who were age and gender matched to renal transplant patients. Patient characteristics 
are described in Table 1. PBMCs were isolated by Ficoll-Hypaque (PAA, Buckinghamshire, 
UK) density gradient centrifugation in a blinded manner and cryopreserved prior to batch 
analysis. 
 
Gene expression analysis 
Peripheral blood was drawn into Tempus Blood RNA Tubes (Life Technologies, Paisley, 
UK), and stored at -20°C. RNA was isolated using the Tempus Spin RNA Isolation kit and 
cDNA was subsequently synthesized using TaqMan Reverse Transcription Reagents (both Life 
Technologies, Paisley, UK). Expression of target genes was measured by quantitative real-time 
PCR platform (qPCR; Fluidigm BioMark) (South San Francisco, CA) where 3 endogenous 
reference genes were used, as previously described
14
.  
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Flow cytometry 
3x10
6
 PBMCs were stained with Live/Dead Aqua (Life Technologies) and antibodies 
specific for the following human markers: anti-CD3-PercP-Cy5.5 (eBioscience), anti-CD20-
Brillian Violet (BV)421 (eBioscience), anti-CD4-AlexaFluor700/PercP-Cy5.5 (eBioscience), 
anti-CD8-APC (eBioscience), anti-CD25-PE (BD), anti-CD14- AlexaFluor647 (BioLegend), 
anti-CD16-PE (eBioscience), anti-CXCR3-FITC (BioLegend), anti-CCR4-PECy-7 (BioLegend), 
anti-CCR6-BV605 (BioLegend) anti-CD161-BV421 (BioLegend), anti-CD45RA APCy-7 
(BioLegend), anti-HLA-DR PECy7 (eBioscience), anti-CD80 CCR6-BV650 (BioLegend), 
CD86-FITC (Invitrogen) and CD163-APC/Cy7 (BioLegend) for 30min at 4°C. Cells were 
acquired on an LSR-Fortessa (BD) with consistent application settings, internal assay-control, 
fluorescence minus ones (FMO) control, isotype controls and/or biological control. Data was 
analysed using FlowJo (Tree Star, Inc. OR, USA) with gating strategies provided in the 
supplemental material, SDC, http://links.lww.com/TP/B475.  
 
Monocyte and CD4
+
T cell isolation and cultures 
Monocytes and CD4
+
T cells were isolated using CD14 Microbeads and the untouched 
CD4
+
T cell Isolation Kit II, respectively (both Miltenyi-Biotec, Cologne, Germany). 
Representative purities are shown in Figure S1, SDC, http://links.lww.com/TP/B475. Cells were 
cultured in X-VIVO (Lonza, Bazel, Switzerland) supplemented with 10% of human serum 
(BioSera, Nuaille, France), 2mM L-glutamine and 100U/mL penicillin/streptomycin (both Life 
Technologies). Monocytes were cultured in the presence or absence of LPS (50μg/mL) for 48h. 
CD4
+
T cells and monocytes were then cocultured at a 2:1 ratio in the presence or absence of 
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soluble αCD3 (10ng/mL) (eBioscience) for 72h. Cytokine production was measured by 
cytometric bead array (CBA) with FCAP Array Software v3.0 (BD). 
 
T cell activation 
CD4
+
T cells were isolated using the human CD4
+
T cell Isolation Kit II (Miltenyi-Biotec) 
and activated with αCD3/CD28 beads (1:2 bead:cell ratio; Life Technologies). CD25 and CD69 
expression was assessed by flow cytometry and cytokine production was measured by CBA 24h 
and 72h postactivation, respectively. 
 
Th17 differentiation  
CD4
+
T cells were activated with anti-CD3/CD28 beads (1:5 bead:cell ratio) and cultured 
in X-VIVO supplemented with 4ng/mL IL-1β, 20ng/mL IL-6, 5ng/mL IL-23, 5ng/mL TGF-β 
10μg/mL anti-IL-4 and 10μg/ml anti-IFN-γ (all from R&D Systems) for 72h. For Th17 
differentiation in the presence of ERK inhibitor, CD4
+
T cells were activated in the presence or 
absence of 0.1μg/mL ERK inhibitor (UO126, Tocris Bioscience) (where the inhibitor or DMSO 
carrier was resupplemented after 36h). Cytokines were analysed at the end of culture by CBA 
(BD). 
 
ERK activation and western blot 
CD4
+
T cells were activated with 5μg/mL plate bound CD3/28 (R&D) in a 96 U-bottom 
plate (5x10
4
 cells/well) for 10min at 37C. Cell pellets were lysed with ice-cold RIPA buffer 
(Thermo Fisher Scientific) containing protease inhibitors 1X (Calbiochem). Samples were 
electrophoresed on 10% SDS polyacrylamide gels and transferred to nitrocellulose membranes. 
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Membranes were incubated with phospho-p44/42 MAPK (Erk1/2; Thr202/Tyr204; #9101, Cell 
Signalling) or p44/42 MAPK (Erk1/2; #9102, Cell Signalling) overnight at 4°C. Proteins were 
detected with chemiluminescence detection reagents (BIORAD) after HRP-conjugated 
secondary antibody incubation using ImageQuant LASS4000 mini and quantified with 
ImageQuant TL software (GE Healthcare Life Science). 
 
Statistical analysis 
Statistical tests were performed using Prism 7 software (GraphPad). For all data in graphs 
summary lines depict mean ± standard error of the mean (SEM) and all individual values are also 
shown. Nonparametric variables between groups were compared using Kruskal-Wallis tests. 
Repeated Measurement (RM) 2-way ANOVA was used to compare 2 related variables between 
groups. Pearson correlation test was used to calculate r and p value between TCR signalling and 
IL-17 production. Posthoc tests are reported in figure legends. Statistical significance is denoted 
as follows: *p<0.05, **p<0.01, *** p<0.001 and **** p<0.0001. 
 
Results 
Tolerant kidney transplant recipients display a reduced Th17 lineage compartment compared 
to healthy controls and patients with chronic-rejection   
To identify differences in T cell responses between healthy volunteers, tolerant patients 
and patients with chronic-rejection (Table 1), peripheral blood samples were compared where the 
expression of T helper(Th) pathway-associated transcription factors and signalling proteins was 
assessed. FOXP3 expression was significantly reduced in patients with chronic-rejection, as 
previously reported
8,9
 (Figure 1A, and Figure S2, SDC, http://links.lww.com/TP/B475). 
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Conversely, no differences were observed in T bet or GATA3 expression between the 3 groups 
analysed. Interestingly, RAR-related orphan receptor C (RORC) was expressed at lower levels in 
tolerant recipients compared to patients with chronic-rejection and healthy controls, suggesting a 
correlation between a reduced Th17 compartment and transplant tolerance (Figure 1A). Gene 
expression analyses of signalling proteins revealed a significantly lower expression of STAT1 
and ERK2 in tolerant recipients, compared to patients with chronic-rejection (Figure 1B). 
Moreover, STAT1, STAT3 and ERK2 were also expressed at lower levels in healthy controls, 
compared to patients with chronic-rejection. Conversely, no significant differences were 
observed in the expression of these genes between healthy volunteers and tolerant recipients 
(Figure S2, SDC, http://links.lww.com/TP/B475). STAT5A and NFKB1 expression was similar 
between the 3 groups analysed (Figure 1B). 
 
We next analysed the phenotype and relative frequencies of T cell subtypes (Figure S3, 
SDC, http://links.lww.com/TP/B475). No differences were observed in the percentage of CD4
+
 
or CD8
+
T cells between the 3 groups was analysed (Figure 1C), nor in the percentage of 
CD4
+
CD45RA
+
 naïve T cells (Figure 1D). This suggested that the reduced RORC gene 
expression observed in tolerant recipients was not due to a higher proportion of naïve T cells in 
circulation
15
. The relative ratio of Th1, Th2 and Th17 cells in the conventional effector memory 
T cell compartment was then assessed where Th1 were defined as CXCR3
+16
, Th2 were 
CCR4
+
CXCR3
-
CCR6
-16 
and Th17 were CCR6
+
CD161
+17
, respectively
 
(Figure S3, SDC, 
http://links.lww.com/TP/B475). We observed that the proportion of Th17 cells was significantly 
lower in tolerant recipients compared to patients with chronic-rejection, further suggesting a link 
between a reduced Th17 compartment and tolerance (Figure 1E). 
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To investigate the function of the patient-derived Th effector cells, total CD4
+
T cells 
were stimulated with CD3/CD28 beads for 72h and production of IFNγ, IL-4 and IL-17 was 
measured by CBA. The amount of IL-17 produced by CD4
+
T cells from tolerant patients was 
lower than CD4
+
T cells from patients with chronic-rejection and healthy volunteers (Figure 1F). 
IL-4 production was also significantly reduced in tolerant recipients compared to healthy 
volunteers, as previously shown
11
. Expression of activation markers CD25 and CD69 in CD4
+
T 
cells was analysed to assess whether the decrease in cytokines secreted by CD4
+
T cells from 
tolerant patients was due to a defect in T cell activation but no significant differences were 
observed (Figure S4, SDC, http://links.lww.com/TP/B475). Together, these data demonstrate 
that tolerant recipients have a reduced peripheral Th17 compartment compared to healthy 
volunteers and patients with chronic-rejection.  
 
Reduced IL-6 production characterized monocytes from tolerant recipients 
To establish the possible mechanisms behind these observations, we investigated whether 
modulating microenvironmental factors, such as local proinflammatory cytokines, influenced the 
differentiation of Th17 cells. Monocytes have been shown to be important for the differentiation 
of Th17 cells due to their capacity to produce IL-6, IL-1β and TNF-α18. We compared the 
proportion of classical (CD14
++
CD16), intermediate (CD14
++
CD16
+
; proinflammatory) and non-
classical (CD14
+
CD16
++
) monocyte subsets
19
 between patients and healthy volunteers (Figure 
2A). The proportion of total monocytes was lower in patients with chronic-rejection compared to 
tolerant recipients, but not significantly different compared to healthy volunteers (Figure 2B). 
CD14
++
CD16
+
 monocytes from patients with chronic-rejection expressed higher levels of the 
activation marker HLA-DR, relative to tolerant patients and healthy volunteers (Figure 2C), 
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although no differences were observed in the expression of other activation markers 
(CD80/CD86) or in any of the other monocyte subsets analysed. 
 
Before investigating the capacity of monocytes to induce IL-17
+
 cells, we assessed the 
response of monocytes to lipopolysaccharide (LPS) activation to control for their capacity to 
secrete IL-6 and TNF-α. Monocytes from tolerant recipients secreted both IL-6 and TNF-α after 
activation, whereas monocytes from patients with chronic-rejection did not respond (Figure 2D, 
Figure S1, SDC, http://links.lww.com/TP/B475). This was likely due to the effects of the 
immunosuppressive drugs which have been shown to influence lymphocyte subset distribution
14
 
and decrease IL-6 production by monocytes
20
. As antithymocyte globulin (ATG) and steroid 
treatment have been shown to induce expression of CD163, we next analysed the expression of 
this marker on monocytes
21
. CD163 was expressed at higher levels on proinflammatory 
monocytes from patients with chronic-rejection, compared to tolerant recipients (Figure 2E), 
suggesting that the immunosuppressive treatment in patients with chronic-rejection could affect 
monocyte responses. 
 
To investigate whether monocytes from tolerant recipients were defective in their ability 
to polarize CD4
+
T cells towards a Th17 phenotype, we next performed cocultures of these cells, 
in the presence of anti-CD3 to activate the T cells, and measured the production of IL-6, TNF-α 
and IL-17 by CBA (Figure 2F, Figure S1, SDC, http://links.lww.com/TP/B475). IL-6, TNF-α 
and IL-17 levels were significantly decreased in cocultures containing tolerant patient-derived 
cells, compared to cocultures containing cells from healthy volunteers (Figure 2F). Conversely, 
monocytes from patients with chronic-rejection did not respond. Overall, these results suggest 
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that impaired cytokine production in the cross-talk between monocytes and T cells from tolerant 
patients may contribute to a reduced Th17 skewing in these patients.  
 
Reduced TCR activation contributes to impaired Th17 polarization in tolerant recipients 
Having confirmed the effect of extrinsic factors in the induction of the Th17 lineage, we 
next assessed the intrinsic capacity of T cells to polarize into Th17 cells. CD4
+
T cells from 
patients and healthy volunteers were stimulated in vitro using a Th17 differentiation cocktail 
(Figure 3A). Despite the presence of all the necessary elements to induce Th17 differentiation, T 
cells from tolerant recipients displayed a resistance to skew towards a Th17 phenotype, relative 
to healthy controls and patients with chronic-rejection (Figure 3A). This implied a potential and 
specific intrinsic defect in T cell from tolerant recipients. 
 
Previous studies have shown that blockade of ERK activation in T cells inhibits Th17 cell 
development in mice and human
22
. Furthermore, we have demonstrated that phosphorylation of 
ERK is impaired in B cells from these tolerant recipients, following BCR activation
11
. As such, 
we next analysed whether the phosphorylation state of ERK in CD4
+
T cells differed between the 
3 groups, after TCR activation. Reduced ERK phosphorylation was observed in CD4
+
T cells 
from tolerant recipients, compared to healthy controls and patients with chronic-rejection (Figure 
3B, Figure S5, SDC, http://links.lww.com/TP/B475). Furthermore, a positive correlation was 
observed between ERK phosphorylation and IL-17 production (Figure 3C). To further 
investigate these findings, we cultured CD4
+
T cells under Th17 skewing conditions in the 
presence of a specific ERK-inhibitor. We found that inhibition of ERK phosphorylation reduced 
IL-17 secretion (Figure 3D), whilst production of a 3
rd
 party cytokine (IL-2) was unaffected 
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(Figure S6, SDC, http://links.lww.com/TP/B475). Together, these data suggest that the reduced 
frequency of circulating Th17 cells in tolerant recipient could be attributed to an impaired 
intrinsic Th17 polarization capacity. 
 
Discussion 
We describe for the first time that tolerant patients exhibit impaired Th17 responses after 
CD3/28 activation and reduced TCR signalling compared to healthy controls and patients with 
chronic-rejection. We also demonstrated that the reduction in TCR signalling in tolerant 
recipients was linked with a decrease in IL-17 production by CD4
+
T cells. Furthermore, reduced 
IL-6 and TNF-α production by monocytes, upon coculture with CD4+T cells, may also contribute 
to the reduction in Th17 responses observed in tolerant recipients. 
 
Previous studies have demonstrated a close relationship between Th17 cells and allograft 
rejection. In 2010, Deteix et al, investigated how the polarization of CD4
+
T cell infiltrates in 
allografts influenced the course of clinical chronic-rejection
23
. Eleven renal allografts were 
explanted from recipients with terminal chronic active rejection and T cell subsets were 
identified in the tissues. Expression of Th-17-associated cytokines (IL-17 and IL-21) was higher 
in grafts which were rejected in < 8 years, compared to grafts which survived > 8 years. 
Conversely, the antiinflammatory cytokine IL-10 was expressed at higher levels in grafts that 
were rejected slower. An analysis of master regulator transcription factors revealed that FOXP3 
and GATA-3 were expressed at higher levels in grafts that survived longer whilst RORC2 was 
expressed more in grafts that were rejected faster. These results demonstrated that a reduced 
proportion of Th17 cells was associated with prolonged graft survival. In our manuscript, we 
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observe Th17 defective responses in patients with long-term graft acceptance in the absence of 
immunosuppression. A year later, Chung et al, investigated the relationship between cellular 
infiltration into allograft tissues and the severity of allograft dysfunction in acute T cell mediated 
rejection
24
. They found that Th17 cell infiltration was significantly associated with allograft 
function and the severity of tissue injury
24
. These authors proceeded to assess effect of 
calcineurin inhibitors in Th1/Th2/Th17 responses and observed in vitro and in vivo that 
tacrolimus suppressed Th1 and Th2, but not Th17 responses
25
. Our results showed a trend for 
patients with chronic-rejection to have fewer circulating CXCR3
+
Th1 cells than healthy 
volunteers and tolerant recipients, as well as a reduction in the production of IL-4, compared to 
healthy volunteers. These results could be explained, at least in part, by the fact that the 
immunosuppressive treatment in patients with chronic-rejection affected their Th1 and Th2 cells, 
but not Th17 cells. 
 
Monocytes from tolerant recipients can produce some IL-6 and TNFα after LPS 
activation but in co-culture with activated T cells this production was deficient, as well as that of 
IL-17. We do not have enough data to dissect whether the reduced cytokine production in the 
cocultures is fundamental for the Th17 defect observed, as this polarization was also reduced in 
the presence of an optimal differentiation cocktail. We also observed that monocytes from CR 
patients secreted negligible levels of TNF-α and IL-6, relative to monocytes from tolerant 
patients, upon LPS-mediated activation; as previously shown this could be due to steroid 
treatment in these
26
.  
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We have previously demonstrated that B cells from tolerant patients have a reduced ERK 
phosphorylation state in B cells following CD40-mediated activation, compared to healthy 
volunteers
11
. The results presented in this manuscript suggest that reduced ERK signaling may 
influence the development and polarization of Th17 cells, as previously reported
22
, and that 
consequently, Th17 polarization and cell-responses may be limited in tolerant recipients. 
Combined with our previous observations of reduced B cell responses in tolerant patients
11
, these 
findings depict that an antiinflammatory environment may contribute to long-term graft 
acceptance. Thus, we have provided novel evidence that an incomplete Th17 pathway integrity 
could contribute to the tolerant state. 
 
The question of whether the responses that we have evidenced are naturally occurring 
before immunosuppression withdrawal or whether these responses are the result of a modified 
graft-host is currently difficult to answer. Our data raise a more important question of whether 
tolerant recipients are donor-specific unresponsive or they could be somewhat immune-deficient. 
Clinically, most of the tolerant recipients maintain good graft function in the absence of 
immunosuppression, but no evidence of increased infections or cancer have been described for 
this population. An estimated 10-year patient survival after the establishment of operational 
tolerance of 90% (95% CI: 75–96), has recently been described27. Clearly, the putative immune-
defect allows them to maintain good graft function and not succumb to other immune-
pathologies, but currently, we do not have any evidence to strongly discern between donor-
specific tolerance or immune-deficient responses.  
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In summary, we have provided novel evidence that an incomplete Th17 pathway integrity 
could contribute to human transplantation tolerance; whether this implies an immune-deficient 
state or not is now open for debate 
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Figure Legends 
 
Figure 1: Tolerant kidney transplant recipients exhibit a reduced Th17 lineage compared to 
healthy controls and patients with chronic-rejection.   
 
(A) Peripheral blood cell gene expression analysis of transcription factors Tbet, GATA3, RORC 
and FOXP3 and (B) signalling proteins STAT1, STAT3, STAT5A, ERK2 and NFKB1 from 
tolerant recipients were compared to healthy volunteers and patients with chronic-rejection. (C) 
The percentage of CD4 and CD8 was measured in peripheral blood CD3
+
 cells from transplant 
recipients and healthy volunteers. (D) The percentage of CD45RA
+
 naive CD4
+
T cells and (E) 
Th1, Th2 and Th17 conventional CD4
+
T cells was measured in the peripheral blood from 
patients and healthy volunteers. (F) IFN-γ, IL-4 and IL-17 production by 2x105 CD4+T cells 
from patients and healthy volunteers was measured by CBA after 72h of anti-CD3/28 activation 
(1:2 bead:cell ratio). Statistical significance was determined using Kruskal-Wallis ANOVAs 
with Dunn’s multiple comparison tests and is denoted as follows: ****=P<0.0001, 
***=P<0.001, **=P<0.01 and *=P<0.05. 
 
Figure 2: Reduced IL-6 production contributes to impaired Th17 polarization in tolerant 
recipients. 
 
(A) Representative dot plots and (B) total percentage of CD14, CD14
++
CD16
-
, CD14
++
CD16
+
 
and CD14
+
CD16
++
 monocytes in peripheral blood samples from patients and healthy volunteers. 
Statistical significance was determined using Kruskal-Wallis ANOVAs with Dunn’s multiple 
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comparison tests. (C) HLA-DR, CD86 and CD80 MFI were measured in monocyte subsets from 
patients and healthy volunteers. Statistical significance was determined using Repeated 
Measurement (RM) 2-Way ANOVAs with Sidak’s multiple comparison tests. (D) IL-6 and 
TNF-α production by 1.25x105 monocytes isolated from patients and healthy volunteers was 
measured after LPS activation (50ng/ml). Statistical significance was determined using RM 2-
Way ANOVAs with Sidak’s multiple comparison tests. (E) CD163 expression was measured in 
monocyte subsets from patients and healthy volunteers. Statistical significance was determined 
using RM 2-Way ANOVAs with Sidak’s multiple comparison tests. (F) IL-6, TNF-α and IL-17 
production was measured in cocultures consisting of 5x10
4
 CD4
+
T cells and 2.5x10
4
 monocytes 
in the presence or absence of soluble 10ng/mL anti-CD3, using cells isolated from patients and 
healthy volunteers. Statistical significance was determined using RM 2-Way ANOVAs with 
Sidak’s multiple comparison tests. Statistical significance is denoted as follows: 
****=P<0.0001, ***=P<0.001, **=P<0.01 and *=P<0.05. 
 
Figure 3: Reduced TCR activation contributes to impaired Th17 polarization in tolerant 
recipients. 
 
(A) IL-17 produced by 2x10
5
 CD4
+
T cells from patients and healthy volunteers was measured 
following anti-CD3/28 activation (1:2 bead:cell ratio) in the presence or absence of a Th17 
polarization cocktail (4ng/mL IL-1β, 20ng/mL IL-6, 5ng/mL IL-23, 5ng/mL TGF-β, 10μg/mL 
αIFN-γ and 10μg/mL αIL-4). Statistical significance was determined using RM 2-Way ANOVAs 
with Tukey’s multiple comparison tests. (B) ERK phosphorylation was measured in CD4+T cells 
following activation with 5ug/mL plate bound anti-CD3/28 for 10min via western blot. 
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Statistical significance was determined using Kruskal-Wallis ANOVAs with Dunn’s multiple 
comparison tests. (C) The correlation between ERK phosphorylation and IL-17 production was 
assessed using a Pearson correlation test to determine statistical significance. (D) IL-17 produced 
by CD4
+
T cells activated with anti-CD3/28 (1:5 bead:cell ratio) in a Th17 polarization cocktail 
in the presence of ERK inhibitor (100ng/ml) or carrier DMSO was measured. Statistical 
significance was determined using RM 2-Way ANOVAs with Fisher’s multiple comparison 
tests. Statistical significance is denoted as follows: **=P<0.01 and *=P<0.05. 
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Figure 1 
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Figure 2 
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Figure 3 
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Table 1: Clinical data of tolerant kidney transplant recipients, patients with chronic-rejection and 
healthy volunteers.  
Patient Data 
Healthy  
Control 
Tolerant 
 
Chronic 
Rejection 
Number of patients 12 17 32 
      Male 10 14 22 
      Female 2 3 10 
Donor (Living/Deceased) - (9/8) (11/21) 
Age in years [mean (range)] 48.0 (23-72) 50.2 (22-77) 44.3 (18-72) 
Recipient age at Transpl [mean (range)]  - 31.3 (11-56) 34.9 (11-62) 
Years immunosuppression free [mean (range)] - 6.1 (1-23) - 
HLA mismatches per group 
 
 
 Number of patients with no mismatches - 6 0 
Number of patients with HLA (A or B) 
mismatches - 2 2 
Number of patients with HLA (A and B) 
mismatches - 1 7 
Number of patients with HLA (A + DR) 
mismatches - 0 3 
Number of patients with HLA (B + DR) 
mismatches - 0 3 
Number of patients with HLA (A, B, DR) 
mismatches - 7 14 
Missing data - 1 3 
Immunosuppressive Regime 
 
 
 
CNI - - 1 
MMF - - 1 
CNI + MMF - - 6 
CNI + Aza - - 2 
CNI + Steroid - - 4 
MMF + Steroids - - 1 
CNI + MMF + Steroids - - 14 
CNI + Aza + Steroids - - 3 
Donor-specific antibodies    
No DSA - 14 16 
DSA Class I - 2 6 
DSA Class II - 1 4 
DSA Class I and II - 0 5 
Missing data  0 1 
Renal Function Parameters    
Creatinine (mmols/L) [mean+SD] - 116.4+38.5 224.9+92.1 
eGFR (mL/min/1.73m
2
) [mean+SD] - 64.9+20.1 32.8+14.1 
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Cell Count    
Lymphocytes count x 10
9
 [mean+SD] 2.18+0.4 2.07+1.2 1.42+0.9 
 
CNI, Calcineurin inhibitor (Cyclosporine or Tacrolimus). Aza, azathioprine. MMF, 
mycophenolate mofetil. DSA: donor-specific antibodies. eGFR: estimated glomerular filtration 
rate. SD: standard deviation. 
  
AC
CE
PT
ED
32 
 
Figure S1: Isolation of CD14
+
monocytes and CD4
+
T cells. Monocytes were isolated using a 
positive selection protocol for CD14
+
 cells. CD4
+
T cells were isolated from the CD14
-
 fraction 
using a negative selection protocol for CD4
+
 cells. Data shown are representative plots of the 
purity of CD14
+
 monocytes and CD14
-
CD4
+
 T cells before and after isolation.     
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Figure S2: Tolerant kidney transplant recipients express lower levels of RORC than healthy 
controls and recipients with chronic rejection. Gene expression of Tbet, GATA3, RORC, 
FOXP3, STAT1, STAT3, STAT5A, ERK2 and NFKB1 was measured in peripheral blood 
samples from tolerant recipients (TOL), healthy volunteers (HC) and patients with chronic 
rejection (CR). Statistical significance was determined using the Kruskal-Wallis test with Dunn’s 
multiple comparisons test where **=P<0.01 and *=P<0.05. 
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Figure S3: Gating strategy to identify T cell subsets. Lymphocytes were identified by forward 
and size scatter after which doublets and dead cells were excluded from the analysis. T cells and 
B cells were identified per their expression of CD3 and CD20, respectively. CD4
+
 and CD8
+
 T 
cells were then subgated from the CD3
+
 population. Naïve and memory T cells were 
distinguished per their expression of CD45RA from the total CD4
+
 T cells. In the CD45RA
-
 
memory population, Tregs were identified as CD4
+
CD25
hi
CD127
lo
 with all other CD4
+
CD45RA
-
 
cells being classified non Tregs or conventional effector memory T cells. From the 
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CD4
+
CD45RA
-
 conventional memory CD4
+
T cells, Th1 cells were identified as CXCR3
+
, Th2 
cells as CCR4
+
CCR6
-
CXCR3
-
 and Th17 cells as CD161
+
 CCR6
+
. The T helper phenotype of all 
analysed subsets was confirmed by measuring cytokine production after TCR activation. 
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Figure S4: CD25 and CD69 expression in patient-derived and healthy control CD4
+
T cells 
following activation. CD4
+
T cells from tolerant recipients (TOL), recipients with chronic 
rejection (CR) and healthy volunteers (HC) were activated with anti-CD3/28 beads (1:2 bead:cell 
ratio) for 24 hours after which the expression of CD25 and CD69 was measured by flow 
cytometry.   
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Figure S5: Standardization of TCR signalling in CD4
+
T cells. ERK phosphorylation (p-ERK) 
was measured in healthy donor-derived CD4
+
T cells (2x10
5
 cells per condition) which were 
activated with 5g/mL plate bound anti-CD3/28 for 0, 10 and 30 minutes, via western blot. 
HSP90 was used as a loading control. Only time point 10 minutes was performed for Figure 3B 
due to low number of cells obtained from patient samples.  
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Figure S6: IL-2 secretion by CD4
+
T cells in the presence of an ERK inhibitor. IL-2 produced by 
CD4
+
T cells activated with anti-CD3/28 (1:5 bead:cell ratio) in the presence of a Th17 
polarization cocktail and 0.1g/mL of an ERK inhibitor or carrier DMSO was measured. 
Statistical significance was determined using RM 2-Way ANOVA, but not differences reached 
statistical significance (P<0.05). 
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